Aldeyra Q3 net loss $14.6M; reproxalap NDA on track for Q4 2022; cash $185M

Aldeyra Therapeutics, Inc.

2022-Q3 EPS reported -$0.84

Net loss of $14.6M ($0.25 per share) for Q3 2022 vs $15.8M ($0.27) for Q3 2021.
Cash, cash equivalents, and marketable securities of $185.3M as of Sep 30, 2022; expected to fund operations through end of 2023.
NDA submission for reproxalap in dry eye disease remains on schedule for Q4 2022; package includes data from five adequate and well-controlled trials.
Pre-NDA meeting with FDA scheduled in Q4 2022 to discuss ADX-2191 for primary vitreoretinal lymphoma; NDA possible by end of 2022.
Top-line results from Phase 2 trial of ADX-629 in acute alcoholic hepatitis expected by end of 2022; ADX-2191 retinitis pigmentosa trial results expected H1 2023.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aldeyra Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $14.6 million, EPS $0.25 per share.

Period: the quarter ended September 30, 2022
Net income: Net loss for the three months ended September 30, 2022 was $14.6 million
EPS: $0.25 per share
Result: reported results

Exact text from the filing

Net loss for the three months ended September 30, 2022 was $14.6 million, or $0.25 per share

View on SEC.gov

Browse all earnings releases →

Aldeyra Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-22-001587

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.